Johnson & Johnson (JNJ) Asset Writedowns and Impairment (2009 - 2026)

Johnson & Johnson has reported Asset Writedowns and Impairment for 18 years, with the latest figure at $184.0 million in Q2 2026.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $184.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $394.0 million (up 603.57% YoY) and the FY2025 annual result came in at $204.0 million, down 49.63% from the prior year.
• Asset Writedowns and Impairment rose to $184.0 million in Q2 2026 per JNJ's latest filing, from $36.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $610.0 million in Q2 2022 and troughed at -$38.0 million in Q3 2023.
• A 5-year average of $213.3 million and a median of $184.5 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2022 and 2024: Asset Writedowns and Impairment soared 4257.14% in 2022, then plunged 94.53% in 2024.
• Over 5 years, Asset Writedowns and Impairment stood at $610.0 million in 2022, then declined by 22.13% to $475.0 million in 2023, then slumped by 94.53% to $26.0 million in 2024, then soared by 211.54% to $81.0 million in 2025, then jumped by 127.16% to $184.0 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $184.0 million, $36.0 million, and $81.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.